Tolerability and Safety of the Oral Thrombin Inhibitor H 376/95 (ximelagatran), Compared to Warfarin, as Stroke Prophylaxis in Patients with Atrial Fibrillation. A Dose-Guiding, Feasibility Multicentre Study (SPORTIF II)
Study identifier:SH-TPA-0002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Tolerability and Safety of the Oral Thrombin Inhibitor H 376/95 (ximelagatran), Compared to Warfarin, as Stroke Prophylaxis in Patients with Atrial Fibrillation. A Dose-Guiding, Feasibility Multicentre Study (SPORTIF II)
Medical condition
venous thromboembolism
Phase
Phase 2
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 May 1999
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
